Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Korean Neurol Assoc. 2019 May;37(2):171-173. Korean. Case Report. https://doi.org/10.17340/jkna.2019.2.9
Cho HJ , Park JM , Park JS .
Department of Neurology, Kyungpook National University Chilgok Hospital, Daegu, Korea. jinforeva@gmail.com
Department of Neurology, Dongguk University College of Medicine, Gyeongju, Korea.
Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea.
Abstract

Nuedexta (dextromethorphan and quinidine) is an Food and Drug Administration approved medication for pseudobulbar affect. Interestingly, this drug was recently reported to improve speech, swallowing, and the ability to handle oral secretions along with emotional lability in amyotrophic lateral sclerosis (ALS) patients with bulbar symptoms. We report a Korean ALS patient whose bulbar function improved after administering Nuedexta for 6 months, extending therapeutic choice of approach in treating ALS patients.

Copyright © 2019. Korean Association of Medical Journal Editors.